Automated production at the curie level of no-carrier-added 6-[<sup>18</sup>F]fluoro-<scp>l</scp>-dopa and 2-[<sup>18</sup>F]fluoro-<scp>l</scp>-tyrosine on a FASTlab synthesizer
作者:C. Lemaire、L. Libert、X. Franci、J.-L. Genon、S. Kuci、F. Giacomelli、A. Luxen
DOI:10.1002/jlcr.3291
日期:2015.6.15
An efficient, fully automated, enantioselective multi-step synthesis of no-carrier-added (nca) 6-[18F]fluoro-L-dopa ([18F]FDOPA) and 2-[18F]fluoro-L-tyrosine ([18F]FTYR) on a GE FASTlab synthesizer in conjunction with an additional high- performance liquid chromatography (HPLC) purification has been developed. A PTC (phase-transfer catalyst) strategy was used to synthesize these two important radiopharmaceuticals. According to recent chemistry improvements, automation of the whole process was implemented in a commercially available GE FASTlab module, with slight hardware modification using single use cassettes and stand-alone HPLC. [18F]FDOPA and [18F]FTYR were produced in 36.3 ± 3.0 % (n = 8) and 50.5 ± 2.7 % (n = 10) FASTlab radiochemical yield (decay corrected). The automated radiosynthesis on the FASTlab module requires about 52 min. Total synthesis time including HPLC purification and formulation was about 62 min. Enantiomeric excesses for these two aromatic amino acids were always >95 %, and the specific activity of was >740 GBq/µmol. This automated synthesis provides high amount of [18F]FDOPA and [18F]FTYR (>37 GBq end of synthesis (EOS)). The process, fully adaptable for reliable production across multiple PET sites, could be readily implemented into a clinical good manufacturing process (GMP) environment.
已开发出一种高效、全自动、无载体添加(nca)的6-[18F]氟-L-多巴([18F]FDOPA)和2-[18F]氟-L-酪氨酸([18F]FTYR)的多步骤对映选择性合成方法,该合成方法在GE FASTlab合成器上进行,并结合额外的高效液相色谱(HPLC)纯化。采用相转移催化(PTC)策略合成这两种重要的放射性药物。根据最近的化学改进,整个过程的自动化已在商业可用的GE FASTlab模块中实现,只需轻微的硬件修改,使用一次性盒式磁带和独立HPLC。[18F]FDOPA和[18F]FTYR的FASTlab放射化学产率(衰变校正)分别为36.3 ± 3.0 %(n = 8)和50.5 ± 2.7 %(n = 10)。在FASTlab模块上的自动放射合成需要大约52分钟。包括HPLC纯化和配方的总合成时间约为62分钟。这两种芳香族氨基酸的对映体过剩总是大于95 %,比活度大于740 GBq/µmol。这种自动化合成提供了大量的[18F]FDOPA和[18F]FTYR(合成结束时大于37 GBq)。该过程完全适用于多个PET站点之间的可靠生产,并可轻松实施到临床良好生产规范(GMP)环境中。